The most common treatment option for AML is chemotherapy to kill the cancerous cells. Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy. If licenced, guadecitabine would offer a new treatment option for patients that cannot tolerate the standard of care chemotherapy treatments.
Seviprotimut-L is a type of cancer vaccine that is being developed for the treatment of adult patients with malignant melanoma who have had surgical resection. It is designed to stimulate the body’s immune system to fight cancer cells, to stop the cancer coming back. Seviprotimut-L is injected under the skin in different parts of the body. The unique way it acts may offer a new treatment option for malignant melanoma patients after surgery.